Global Dermatology Diagnostic Devices and Therapeutics Market Will Expand At A Formidable CAGR Of 7.0% During The Forecast Period 2017 - 2024

Researchmoz added Most up-to-date research on "Global Dermatology Diagnostic Devices and Therapeutics Market Will Expand At A Formidable CAGR Of 7.0% During The Forecast Period 2017 - 2024" to its huge collection of research reports.

This report on the global dermatology diagnostic devices and therapeutics market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.

The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global dermatology diagnostic devices and therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global dermatology diagnostic devices and therapeutics market.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=631774

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2017 to 2024 are provided for all the segments, considering 2016 as the base year. Market size estimations involved in-depth study of product features of different types of diagnostic devices and therapeutics. Additionally, market related factors such as increasing preference for technologically advanced services, product innovation, and increasing prevalence of acute skin conditions, chronic skin conditions, skin infections and other dermatology diseases in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Dermatology Diagnostic Devices and Therapeutics Market: Segmentation

Based on product type, the global dermatology diagnostic devices market has been segmented dermatoscopes, microscopes & trichoscopes, and imaging equipment. These segments are further categorized into sub-segments such as contact oil immersion devices, cross-polarized devices and hybrid devices in dermatoscope segment; multispectral confocal microscope, reflectance confocal microscope, Raman spectroscope, and others in dermatology microscopes and trichoscopes segment; and imaging equipment are sub-segmented into x-ray, magnetic resonance imaging, ultrasound, optical coherence tomography, and others.

Based on the drug class, global dermatology therapeutics market is sub-segmented into antibacterial agents, antifungal agents, antiviral agents, corticosteroids, retinoids, immunosuppressant, and biologics.

Browse TOC @ https://www.researchmoz.us/dermatology-diagnostic-devices-and-therapeutics-market-devices-and-drug-class-global-industry-analysis-size-share-growth-trends-and-forecast-2015-2023-report.html/toc

Geographically, the global dermatology diagnostic devices and therapeutics market has been segmented into six regions: North America, Europe, Asia Pacific, Latin America, Middle East & North Africa, and Rest of the World. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, China, Japan, India, Australia, Brazil, Egypt, Kuwait, Saudi Arabia, and UAE.

Dermatology Diagnostic Devices and Therapeutics Market: Vendor Analysis

The report also profiles major players in the dermatology diagnostic devices and therapeutics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Agfa-Gevaert N.V., Astellas Pharma, Inc., Cutera, Inc., Dino-Lite Europe/IDCP B.V., Galderma S.A., Genentech, a Roche Company, GlaxoSmithKline plc., LEO Pharma A/S, Michelson Diagnostics Ltd., Novartis International AG, Valeant Pharmaceuticals International, Inc., Canfield Scientific, Inc.

Global Dermatology Diagnostic Devices Market, by Product Type

• Dermatoscopes
  • Contact Oil Immersion Dermatoscope
  • Cross-Polarized Dermatoscopes
  • Hybrid Dermatoscope
• Microscopes and Trichoscopes
  • Multispectral Photoacaustic Microscopy (PAM)
  • Reflectance Confocal Microscopy (RCM)
  • Raman Spectroscopy
  • Others
• Imaging Equipment
  • X-ray
  • Magnetic Resonance Imaging (MRI)
  • Ultrasound
  • Optical Coherence Tomography (OCT)
  • Others

Global Dermatology Therapeutics Market, by Drug Class

• Antibacterial Agents
• Antifungal Agents
• Antiviral Agents
• Corticosteroids
• Retinoids
• Immunosuppressants
• Biologics

Global Dermatology Diagnostic Devices and Therapeutics Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & North Africa
  • Egypt
  • Kuwait
  • Saudi Arabia
  • UAE
  • Rest of Middle East & North Africa
• Rest of the World (RoW)

Clinical Trails On Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

Researchmoz added Most up-to-date research on "Clinical Trails On Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation" to its huge collection of research reports.

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare autoimmune disorders such as scleroderma, to very common conditions such as acne vulgaris and atopic dermatitis. For the past decade the majority of the therapeutic dermatology market has been saturated and highly genericized, and strongly dominated by small molecules. There is a significant unmet need for more efficacious and safer treatment options, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues with the long-term use of many available treatments.

Although the scope of dermatological disorders is diverse in terms of severity, clinical presentation, and key patient demographics, there is a degree of crossover between many indications in terms of their underlying pathophysiology. Increased inflammation and aberrant immune response resulting in skin barrier dysfunction are commonly shared causes. Infections and dysfunctions in wound healing are also common causes of dermatological diseases.

Scientific advancements over the course of recent decades have revealed a broad range of novel potential molecular targets, enabling the advancement of a previously stagnant field. This is reflected in the high number of products being developed, with 961 pipeline products currently in the dermatology therapy area pipeline.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1217021

Analysis indicates that the current pipeline is following a trend of focusing on innovative biologic therapies, following the clinical and commercial success of such therapies in the treatment of psoriasis. There are various biologics in the pipeline for major skin disorders - including atopic dermatitis, acne vulgaris and rosacea - for which there is a significant unmet need in patients with moderate-to-severe conditions.

Moreover, there is a considerable degree of innovation present in the therapy area, as there are a total of 197 first-in-class pipeline products in development for dermatological indications, representing 32% of the 617 pipeline products for which there is a disclosed molecular target. Many of these appear promising in terms of safety and efficacy, and carry a significant potential to strengthen the treatment landscape for various dermatological conditions.

Browse TOC @ https://www.researchmoz.us/frontier-pharma-dermatology-intracellular-signal-transducers-and-cytokine-signaling-molecules-dominate-pipeline-and-first-in-class-innovation-report.html/toc

Scope
- With 961 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future dermatology market?
- There are 197 first-in-class products in the dermatology pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- The majority of first-in-class products are in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
- A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy- Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
- Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Pharma Point: Overview Of Dermatology Therapeutics Drug Development Market

Researchmoz added Most up-to-date research on "Pharma Point: Overview Of Dermatology Therapeutics Drug Development Market" to its huge collection of research reports.

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.
Overall, the dermatology pipeline is highly innovative, owing to the advancements in the understanding of the disease pathways of many skin disorders. The number of strong late-stage products and substantial early-stage segment of this active and diverse pipeline are strong indicators of long-term growth in this market.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=984798

The report provides comprehensive information on the pipeline development landscape for is Acne vulgaris, Psoriasis and Atopic dermatitis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

• Which companies are the most active within the pipeline for dermatology?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in this disease area?

Browse TOC @ https://www.researchmoz.us/enquiry.php?type=S&repid=984798

Reasons to buy

• Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
• Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
• Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
• Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 13
Introduction 15
GBI Research Report Coverage 15
Acne Vulgaris Overview 15
Psoriasis Overview 15
Atopic Dermatitis Overview 15
Therapeutics Development 16
Acne Vulgaris 16
Psoriasis 18
Atopic Dermatitis 20
Therapeutics under Development by Companies 22
Acne Vulgaris 22
Psoriasis 24
Atopic Dermatitis 31
Therapeutics under Investigation by Universities/Institutes 34

Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

Researchmoz added Most up-to-date research on "Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation" to its huge collection of research reports.

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct dermatological conditions are thought to exist, ranging from rare autoimmune disorders such as scleroderma, to very common conditions such as acne vulgaris and atopic dermatitis. For the past decade the majority of the therapeutic dermatology market has been saturated and highly genericized, and strongly dominated by small molecules. There is a significant unmet need for more efficacious and safer treatment options, as physicians often cite poor efficacy, low patient compliance and problematic safety profiles as issues with the long-term use of many available treatments.

Although the scope of dermatological disorders is diverse in terms of severity, clinical presentation, and key patient demographics, there is a degree of crossover between many indications in terms of their underlying pathophysiology. Increased inflammation and aberrant immune response resulting in skin barrier dysfunction are commonly shared causes. Infections and dysfunctions in wound healing are also common causes of dermatological diseases.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1217021

Scientific advancements over the course of recent decades have revealed a broad range of novel potential molecular targets, enabling the advancement of a previously stagnant field. This is reflected in the high number of products being developed, with 961 pipeline products currently in the dermatology therapy area pipeline.

Analysis indicates that the current pipeline is following a trend of focusing on innovative biologic therapies, following the clinical and commercial success of such therapies in the treatment of psoriasis. There are various biologics in the pipeline for major skin disorders - including atopic dermatitis, acne vulgaris and rosacea - for which there is a significant unmet need in patients with moderate-to-severe conditions.

Moreover, there is a considerable degree of innovation present in the therapy area, as there are a total of 197 first-in-class pipeline products in development for dermatological indications, representing 32% of the 617 pipeline products for which there is a disclosed molecular target. Many of these appear promising in terms of safety and efficacy, and carry a significant potential to strengthen the treatment landscape for various dermatological conditions.

Browse TOC @ https://www.researchmoz.us/frontier-pharma-dermatology-intracellular-signal-transducers-and-cytokine-signaling-molecules-dominate-pipeline-and-first-in-class-innovation-report.html/toc

Scope

- With 961 products in active development, the pipeline is considerably large. How will pipeline innovation affect the future dermatology market?
- There are 197 first-in-class products in the dermatology pipeline. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
- The majority of first-in-class products are in development for indications involving inflammation. Which first-in-class targets are most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
- A significant number of first-in-class products have been identified with no prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy

- Understand the current clinical and commercial landscape. The report includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
- Visualize the composition of the dermatology market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
- Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating dermatological diseases, including rare conditions.
- Assess the therapeutic potential of first-in-class targets. Using proprietary matrices, first-in-class products have been assessed and ranked according to clinical potential. The matrices have been split into three categories: inflammatory diseases, infectious diseases, and wounds/scars. Promising targets have been reviewed in greater detail.
- Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Global Dermatology Diagnostic Devices and Therapeutics Market Driven by Rising Air Pollution, 2016 - 2024

Researchmoz added Most up-to-date research on "Global Dermatology Diagnostic Devices and Therapeutics Market Driven by Rising Air Pollution, 2016 - 2024" to its huge collection of research reports.

This report on the global dermatology diagnostic devices and therapeutics market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments.
The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment and sub-segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global dermatology diagnostic devices and therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also includes market attractiveness analysis that provides a thorough analysis of the overall competitive scenario in the global dermatology diagnostic devices and therapeutics market.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market size estimations involved in-depth study of product features of different types of diagnostic devices and therapeutics. Additionally, market related factors such as increasing preference for technologically advanced services, product innovation, and increasing prevalence of acute skin conditions, chronic skin conditions, skin infections and other dermatology diseases in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=631774

Dermatology Diagnostic Devices and Therapeutics Market: Segmentation
Based on product type, the global dermatology diagnostic devices market has been segmented dermatoscopes, microscopes & trichoscopes, and imaging equipment. These segments are further categorized into sub-segments such as contact oil immersion devices, cross-polarized devices and hybrid devices in dermatoscope segment; multispectral confocal microscope, reflectance confocal microscope, Raman spectroscope, and others in dermatology microscopes and trichoscopes segment; and imaging equipment are sub-segmented into x-ray, magnetic resonance imaging, ultrasound, optical coherence tomography, and others.

Based on the drug class, global dermatology therapeutics market is sub-segmented into antibacterial agents, antifungal agents, antiviral agents, corticosteroids, retinoids, immunosuppressant, and biologics.

Geographically, the global dermatology diagnostic devices and therapeutics market has been segmented into six regions: North America, Europe, Asia Pacific, Latin America, Middle East & North Africa, and Rest of the World. In addition, the regions have been further segmented by major countries from each region. These include the U.S., Canada, the U.K., Germany, China, Japan, India, Australia, Brazil, Egypt, Kuwait, Saudi Arabia, and UAE.

Dermatology Diagnostic Devices and Therapeutics Market: Geographical and Competitive Dynamics
The report also profiles major players in the dermatology diagnostic devices and therapeutics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Agfa-Gevaert N.V., Astellas Pharma, Inc., Cutera, Inc., Dino-Lite Europe/IDCP B.V., Galderma S.A., Genentech, a Roche Company, GlaxoSmithKline plc., LEO Pharma A/S, Michelson Diagnostics Ltd., Novartis International AG, Valeant Pharmaceuticals International, Inc., Canfield Scientific, Inc.

Global dermatology diagnostic devices and therapeutics market has been segmented as follows:

Global Dermatology Diagnostic Devices Market, by Product Type
Dermatoscopes

• Contact Oil Immersion Dermatoscope
• Cross-Polarized Dermatoscopes
• Hybrid Dermatoscope

Microscopes and Trichoscopes

• Multispectral Photoacaustic Microscopy (PAM)
• Reflectance Confocal Microscopy (RCM)
• Raman Spectroscopy
• Others

Imaging Equipment

• X-ray
• Magnetic Resonance Imaging (MRI)
• Ultrasound
• Optical Coherence Tomography (OCT)
• Others

Global Dermatology Therapeutics Market, by Drug Class

• Antibacterial Agents
• Antifungal Agents
• Antiviral Agents
• Corticosteroids
• Retinoids
• Immunosuppressants
• Biologics

Global Dermatology Diagnostic Devices and Therapeutics Market, by Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe

Browse More Details @ http://www.researchmoz.us/dermatology-diagnostic-devices-and-therapeutics-market-devices-and-drug-class-global-industry-analysis-size-share-growth-trends-and-forecast-2015-2023-report.html

Forecast Till 2022: Global Dermatology Market - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth

ResearchMoz presents this most up-to-date research on "Forecast Till 2022: Global Dermatology Market - Innovative Pipeline and Increasing Uptake of Biologics to Diversify Treatment Options and Drive Strong Growth".

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition.For the past decades, the majority of the dermatology market has remained saturated with established products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

This report covers all dermatological disorders, but there is a particular focus on three key diseases: atopic dermatitis, acne vulgaris and psoriasis, as these conditions have the highest prevalence and the largest pipeline. The global dermatology market was valued at $20.0 billion in 2015, and is projected to grow at a considerable Compound Annual Growth Rate (CAGR) of 7.73%, reaching $33.7 billion in 2022. Key drivers of this growth will be the uptake of recently approved premium biologics, as well as promising late-stage products that are expected to be highly valuable.

Scope

The dermatology market landscape is expected to change substantially with the advent of promising novel pipeline products.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=725316

Overall, there are 801 dermatology products in the pipeline, with biologics representing 37% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.

• Which molecular targets are most prominent within the pipeline?
• How do the key indications differ in terms of molecule type?
• How does the composition of the pipeline compare with that of the existing market?
• What mechanisms of action are most common for pipeline drugs?

Global revenues for the dermatology market are forecast to grow at a CAGR of 7.73%, from $20 billion in 2015 to $33.7 billion in 2022.

• Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
• Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
• What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to - 

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
• Visualize the composition of the dermatology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
• Analyze the dermatology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications.
• Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
• Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various dermatological conditions.
• Identify commercial opportunities in the dermatology deals landscape by analyzing trends in licensing and co-development deals.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=725316